Yohei Doi
Impact in
- Molecular Medicine top 0.01%
- Antibiotic Resistance in Bacteria
- Applied Microbiology and Biotechnology top 0.02%
- Antibiotic Use and Resistance
Papers in
-
- Antibiotic Resistance in Bacteria 310
- Endocrinology 114
- Vibrio bacteria research studies 53
- Enterobacteriaceae and Cronobacter Research 29
- Co-authors
- David L. Paterson (42 shared papers)David van Duin (25 shared papers)Guo‐Bao Tian (26 shared papers)Jian–Hua Liu (10 shared papers)Yoshichika Arakawa (28 shared papers)Ryan K. Shields (42 shared papers)Luchao Lv (6 shared papers)Jennifer M. Adams‐Haduch (36 shared papers)
- Journals
- Antimicrobial Agents and Chemotherapy (89 papers)Clinical Infectious Diseases (32 papers)Open Forum Infectious Diseases (24 papers)Journal of Antimicrobial Chemotherapy (21 papers)Emerging infectious diseases (21 papers)
- Partner nations
- United StatesJapanChina
In The Last Decade
Yohei Doi
442 papers receiving 28.9k citations
Yohei Doi's Hit Papers
Peers
Comparison fields: 5 of 174
- Molecular Medicine 20.9k
- Applied Microbiology and Biotechnology 3.2k
- Endocrinology 6.2k
- Pollution 4.7k
- Pharmacology 5.6k
Countries citing papers authored by Yohei Doi
This map shows the geographic impact of Yohei Doi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yohei Doi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yohei Doi more than expected).
Fields of papers citing papers by Yohei Doi
This network shows the impact of papers produced by Yohei Doi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yohei Doi. The network helps show where Yohei Doi may publish in the future.
Co-authors
The 25 scholars most cited alongside Yohei Doi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 461 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study Hit paper breakdown → | 2015 | 4496 |
| 2 | The global epidemiology of carbapenemase-producing Enterobacteriaceae Hit paper breakdown → | 2016 | 786 |
| 3 | Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial Hit paper breakdown → | 2020 | 678 |
| 4 | Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019) Hit paper breakdown → | 2020 | 567 |
| 5 | Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae Hit paper breakdown → | 2017 | 560 |
| 6 | Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections Hit paper breakdown → | 2019 | 502 |
| 7 | 2007 | 484 | |
| 8 | Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens Hit paper breakdown → | 2012 | 476 |
| 9 | Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections Hit paper breakdown → | 2016 | 432 |
| 10 | Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia Hit paper breakdown → | 2017 | 424 |
| 11 | 2017 | 417 | |
| 12 | 2016 | 392 | |
| 13 | Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection Hit paper breakdown → | 2018 | 339 |
| 14 | 2015 | 335 | |
| 15 | 2017 | 296 | |
| 16 | 2003 | 290 | |
| 17 | 2016 | 280 | |
| 18 | 2020 | 273 | |
| 19 | 2012 | 265 | |
| 20 | 2021 | 262 |
About Yohei Doi
Yohei Doi is a scholar working on Molecular Medicine, Endocrinology, Pharmacology, Applied Microbiology and Biotechnology and Infectious Diseases, having authored 461 papers that have together received 29.5k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (310 papers), Antibiotics Pharmacokinetics and Efficacy (84 papers), Vibrio bacteria research studies (53 papers), Bacterial Identification and Susceptibility Testing (41 papers), Pharmaceutical and Antibiotic Environmental Impacts (38 papers), Antibiotic Use and Resistance (38 papers), Enterobacteriaceae and Cronobacter Research (29 papers) and Urinary Tract Infections Management (27 papers). The work is most often cited by research in Molecular Medicine (20.9k citations), Applied Microbiology and Biotechnology (3.2k citations), Endocrinology (6.2k citations), Pollution (4.7k citations) and Pharmacology (5.6k citations). Yohei Doi has collaborated with scholars based in United States, Japan and China. Frequent co-authors include David L. Paterson, David van Duin, Guo‐Bao Tian, Jian–Hua Liu, Yoshichika Arakawa, Ryan K. Shields, Luchao Lv, Jennifer M. Adams‐Haduch, Xi Huang and Robert A. Bonomo. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, Open Forum Infectious Diseases, Journal of Antimicrobial Chemotherapy and Emerging infectious diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.